Monoclonal antibody PH7 has specificity for the phosphorylated form of the human liver phenylalanine hydroxylase and negligible reactivity towards the dephosphorylated form of the native enzyme by enzyme-linked immunoassay. PH7 binds specifically to the phosphorylated form of the liver enzyme after SDS/polyacrylamide-gel electrophoresis and transfer to nitrocellulose. Competitive blocking assays have been applied in conjunction with reversed-phase h.p.l.c. of purified tryptic fragments of human liver phenylalanine hydroxylase to localize the epitope. The major immunoreactive tryptic peptide cross-reacting with PH7 had an amino acid analysis corresponding to the first 41 amino acids of the human liver phenylalanine hydroxylase sequence and included the serine residue that is thought to be the phosphorylation site. The monoclonal antibody recognized the phosphorylated form of the synthetic decapeptide corresponding to the local phosphorylation-site sequence Gly-Leu-Gly-Arg-Lys-Leu-Ser(P)-Asp-Phe-Gly, but not the dephosphodecapeptide. Thermolysin digestion of the peptide demonstrated the monoclonal antibody bound to the pentapeptide Leu-Ser(P)-Asp-Phe-Gly. Monoclonal antibody PH7 recognized the phosphodecapeptide at concentrations 103-fold higher than with phenylalanine hydroxylase, compared with 104-107-fold higher for other phosphopeptides and phosphoproteins. The results demonstrate that monoclonal antibody PH7 has specificity for the phosphorylated form of phenylalanine hydroxylase at the phosphorylation site.
INTRODUCTION
In mammalian liver, phenylalanine hydroxylase (phenylalanine 4-mono-oxygenase, EC 1.14.16.1) catalyses the conversion of phenylalanine into tyrosine [for reviews, see Kaufman (1976) , Cotton (1977) and Goodwin (1979) ]. The activity of the hepatic enzyme can be modulated by a number of effectors including phenylalanine, lysophosphatidylcholine (Fisher & Kaufman, 1972 ) and phosphorylation (Abita et al., 1976; Donlon & Kaufman, 1977) . It would be advantageous to relate the biological function of the phenylalanine hydroxylase molecule with the amino acid sequence by using monoclonal antibodies directed to single antigenic determinants (Kohler & Milstein, 1975 , 1976 ). We have previously described the production of a library of monoclonal antibodies generated against mammalian liver phenylalanine hydroxylase to aid in the analysis of structure-function relationships (Choo et al., 1979; Jennings et al., 1986 ).
The present paper demonstrates that monoclonal antibody PH7 binds specifically to the phosphorylated form of human liver phenylalanine hydroxylase and identifies the principal part of the binding site. Monoclonal antibody PH7 binds to a linear sequence of five amino acids containing the phosphorylation site. Moreover, monoclonal antibody PH7 binding requires the phosphoserine residue for binding to this pentapeptide.
EXPERIMENTAL PROCEDURES Materials
Human liver phenylalanine hydroxylase was prepared (95% pure) by affinity chromatography using a monoclonal-antibody immuno-affinity column (Choo et al., 1979) . Procedures for the phosphorylation and enzyme dephosphorylation of affinity-purified human liver enzyme have been detailed (Smith et al., 1984) . The stoichiometry of phosphorylation of the affinitypurified, phosphorylated and enzymically dephosphorylated forms of the human liver phenylalanine hydroxylase are 0.3 mol, 0.05 mol and 0.6 mol of 32P/mol of human phenylalanine hydroxylase monomer respectively.
The catalytic subunit of the cyclic AMP-dependent protein kinase was prepared from bovine heart muscle (Sugden et al., 1976) . Methods for the preparation, Vol. 244 Abbreviations used: Tos-Phe-CH2Cl, tosylphenylalanylchloromethane ('TPCK'); e.l.i.s.a., enzyme-linked immunosorbent assay; PTH, phenylthiohydantoin.
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isolation and screening of murine hybridoma lines generating monoclonal antibodies PH7, PH8 and PH9 directed against phenylalanine hydroxylase have been described (Jennings et al., 1986 Antibody-binding assay Antigenic reactivity was determined by an e.l.i.s.a. method as previously described (Jennings et al., 1986) . Samples of antigenic preparations to be tested [0.05 ml of phosphorylated and dephosphorylated human liver phenylalanine hydroxylase/well; 2,g/ml of 10 mMTris/HCl (pH 7.4)/ 10 mM-phenylalanine/0. 1 mm-EDTA] were coated on wells overnight at 4 'C. Binding of monoclonal antibodies was determined by colour development with peroxidase-conjugated goat antimouse antisera (Cappel Laboratories, Cochranville, PA, U.S.A.) and o-phenylenediamine (BDH). The A492 was recorded with a Titertek Multiskan Instrument (Flow Laboratories, North Ryde, Australia). For competitive antibody-blocking experiments, the competing peptides or proteins were pre-incubated with monoclonal antibody for 1 h at 4 'C before addition to microtitre plates coated with affinity-purified phenylalanine hydroxylase. The dilution of antibody used in competitive e.l.i.s.a. was determined as below saturation of antigenic sites. Incubation was for 1 h at 4 'C before washing, addition of enzyme conjugate, followed by substrate.
Electrophoretic transfer and immunodetection
Human liver phenylalanine hydroxylase and human liver extract were subjected to SDS/polyacrylamide-gel electrophoresis (Smith et al., 1984 (Smith et al., 1984) . The blots were washed, air-dried and autoradiographed.
Preparation of tryptic fragments of human liver phenylalanine hydroxylase Phosphorylated human liver enzyme was reduced and carboxymethylated then digested (50: 1) with Tos-PheCH2Cl-treated trypsin in 0.05 M-NH4HCO3, pH 8.0, for 6 h at 37 'C. Proteolysis was stopped by boiling the sample for 10 min. The digests were freeze-dried and then subjected to blocking e.l.i.s.a. or separation of peptides by h.p.l.c.
Peptide separation by h.p.l.c.
Tryptic peptides of phenylalanine hydroxylase were separated by reversed-phase h.p.l.c. using either a 0.3 cm x 20 cm column of Lichrosorb C8 (5 ,tm particle size; Merck; part no. 50322-1) or a 0.46 cm x 25 cm column of Aquapore RP 300 (10 gm particle size; Brownlee Laboratories, Santa Clara, CA, U.S.A.; part no. C03-lOA). Details of the separation conditions are given in the Results section.
Peptide sequence analysis
Selected peptides were subjected to automated Edman degradation and PTH-amino acids were analysed as described by Simpson et al. (1980) .
Peptide synthesis
The synthetic peptides Gly-Leu-Gly-Arg-Lys-Leu-SerAsp-Phe-Gly (peptide A) and Leu-Arg-Arg-Ala-Ser-LeuGly (peptide B) were assembled using the method of Hodges & Merrifield (1975) on an Applied Biosystems synthesizer, model 430A. The peptide amides were cleaved by HF treatment and purified by ion-exchange chromatography on sulphopropyl-Sephadex as described previously (Kemp, 1979) . Peptide purity was 99O% as judged by analytical reversed-phase h.p.l.c. The amino acid composition of peptide A determined after acid hydrolysis (5.7 M-HCl for 24 h at 110 'C) was as follows: GlY2S90 LeU2.05 Argl.00 Lys1-04 Serl.05 Asp1.02 Pheo096. The amino acid composition of peptide B was as previously described (Kemp, 1979) .
Phosphorylation of the synthetic peptides was carried out as described previously (Smith et al., 1984) . Stoichiometric phosphorylation was confirmed by h.p.l.c. analysis and high-voltage paper electrophoresis at pH 1.9. Partially hydrolysed phosphopeptide (5.7 M-HCI, 2 h, 40 'C) contained phosphoserine as assessed by high-voltage paper electrophoresis at pH 1.9 (Smith et al., 1984) .
Competitive e.l.i.s.a. was performed on the peptides as described above.
Proteolytic cleavage of the synthetic peptide
The phosphorylated synthetic peptide A was subjected to digestion with trypsin and thermolysin. Digestion was performed in 100 mM-NH4HCO3 pH 8.0 at 37 'C with an enzyme/substrate ratio of 1: 1 (w/w) for 4 h.
The proteolytic digests were then separated by reversed-phase h.p.l.c. using the Brownlee RP300 column equilibrated in 0.1 % trifluoroacetic acid as described in the Experimental procedures section. The u.v. profile was observed at 215 nm and the h.p.l.c. run was screened by competition e.l.i.s.a to detect immunoreactive peptides.
1987 RESULTS Specificity of monoclonal antibody PH7 for phosphorylated human liver phenylalanine hydroxylase Initial characterization of the monoclonal antibody PH7-defined antigenic determinant using an e.l.i.s.a. technique demonstrated apparent specificity of monoclonal antibody PH7 for human liver phenylalanine hydroxylase after phosphorylation with cyclic AMPdependent protein kinase (Fig. la) . The binding was dependent on the phosphorylation state, since there was negligible reactivity with the dephosphorylated form of the human liver enzyme (Fig. lb) . Previous testing of two
monoclonal antibodies PH8 and PH9 against phenylalanine hydroxylase has demonstrated that these antibodies do not compete with PH7 binding to phenylalanine hydroxylase (Jennings et al., 1986) . As controls, the two monoclonal antibodies, PH8 and PH9 demonstrated equivalent cross-reactivity with both phosphorylated and enzymically dephosphorylated forms of the liver enzyme. Monoclonal antibodies PH7 and PH8 were used at a 1: 200000 dilution, whereas PH9 was used at a 1:50000 dilution in the e.l.i.s.a. to give below saturation point in the competition.
Binding of monoclonal PH7 to phosphorylated human liver phenylalanine hydroxylase transferred to nitroceliulose
Since the binding of monoclonal antibody PH7 to human phenylalanine hydroxylase might be sensitive to change in the native protein structure, we decided to find out whether the immunoreactivity of the antigenic determinant was abolished by SDS treatment. Phosphorylated, dephosphorylated and affinity-purified human liver enzymes were separated by SDS/polyacrylamide-gel electrophoresis, transferred to nitrocellulose and subjected to immunodetection using the monoclonal antibodies PH7 and PH9. Amido Black staining of the nitrocellulose after electrophoretic blotting indicated (a) the same amount of phosphorylated and dephosphorylated forms of enzyme were transferred.
It has been previously demonstrated that the dephosphorylated form of phenylalanine hydroxylase has an apparent M, of 49000 and can be converted into the Mr-50000 phosphorylated form by phosphorylation in the presence of cyclic AMP-dependent protein kinase (Smith et al., 1984) . As indicated in Fig. 2 , monoclonal antibody PH7 demonstrated specificity for the phosphorylated form (Fig. 2a, lanes 1 and 3) , with no detectable cross-reactivity with the dephosphorylated enzyme (Fig. 2a, lanes 2 and 3) . By contrast, monoclonal antibody PH9 demonstrated equivalent cross-reactivity with both forms of the enzyme (Fig. 2b) . A similar result was obtained when monoclonal antibody PH7 was used to probe nitrocellulose filters containing reduced and carboxymethylated human liver phenylalanine hydroxylase (results not shown).
These results indicate that the sequence-specific rather than conformational nature of the antigenic determinant was recognized by monoclonal antibody PH7, since there was no modification in immunoreactivity on incubation with denaturing or chemical agents.
Characterization of PH7-inmunoreactive peptide
In initial experiments designed to localize the monoclonal-antibody-PH7 antigenic site, carboxymethylated phosphorylated human liver phenylalanine hydroxylase was digested with trypsin at 37°C and the mixture of tryptic fragments subjected to competitive blocking immunoassays. The results obtained indicated that antigenicity was retained after digestion with trypsin (results not shown). The black bar at 27 min defines the position of fraction T1-7, the immunoreactive component.
1987 (Fig. 3) . The effluent fractions were monitored by competitiveblocking immunoassay and counting of radioactivity to detect 32P-labelled tryptic peptides. A significant proportion of the applied PH7 immunoreactivity was recovered as a major peak eluted at 35 min and a smaller peak eluted at 32 min (Fig. 3) . Coincident with the elution of the immunoreactive peaks was the emergence of two peaks of 32p radioactivity (Fig. 3) . There was also a large peak of radioactivity at the start of the h.p.l.c. run which coincides with unincorporated [32P]ATP. Purification of immunoreactive peptide A tryptic digest of reduced, carboxymethylated phenylalanine hydroxylase was fractionated by reversedphase h.p.l.c. on a 0.46 cm x 25 cm Aquapore RP 300 column using a linear gradient of acetonitrile at pH 8.0 (Fig. 4a) . Two peaks of immunoreactivity (cf. Fig. 3 ) were detected, a major one at 19 min (TI) and a lesser one at 21 min (T2). The major peak of immunoreactivity was further fractionated on the same column with a linear gradient of acetonitrile in 0.10% trifluoroacetic acid (Fig. 4b) . At least seven distinct components could be identified, one of which eluted at 27 min (TI-7) and cross-reacted strongly with PH7.
The amino acid composition of peptide TI-7 is given in Table 1 . It corresponds closely to residues 1-41 of the reported amino acid sequence of phenylalanine hydroxylase (Kwok et al., 1985) . Amino-acid-sequence determination gave no detectable PTH-amino acid, indicating that the N-terminus of the peptide was blocked, which is consistent with the reported N-terminal residue acetylserine (Kwok et al., 1985) .
Attempts to obtain a small immunoreactive peptide with an unblocked N-terminus by subdigestion of T1-7 with various enzymes were unsuccessful.
Immunoreactive test of synthetic peptides
The peptide homologous with the phosphopeptide isolated from rat liver phenylalanine hydroxylase (Wretborn et al., 1980) was synthesized. Monoclonal antibody PH7 has been previously shown to cross-react with rat liver phenylalanine hydroxylase (Jennings et al., 1986 ). This peptide sequence corresponds to residues 10-19 of the reported human phenylalanine hydroxylase sequence (Kwok et al., 1985) . The decapeptide synthesized was a substrate for the kinase, as phosphoserine was isolated by cleavage (Smith et al., 1984) and behaved similarly to the phenylalanine hydroxylase in that the antibody PH7 recognized this peptide only in the phosphorylated state (Fig. 5) Table 1 ). This shows that the antibody still recognizes the peptides Lys-Leu-Ser(P)-Asp-Phe-Gly and Leu-Ser(P)-AspPhe-Gly.
Cross-reactivity of monoclonal antibody PH7 with other phosphoproteins and phosphopeptides Several known phosphoproteins were tested to demonstrate the specificity of monoclonal antibody PH7. In the competitive e.l.i.s.a., 75 pmol of phosphorylated synthetic peptide A gave 50% competition ofmonoclonal antibody PH7 (dilution 1:100000) binding to phenylalanine hydroxylase (Fig. 5 and Table 2 ). By contrast, casein and phosvitin, both containing multiple bound phosphate, required 33 nmol and 96 nmol of Pi respectively for 50% competition ( Table 2 ).
The phosphorylated synthetic peptide B, Lys-ArgArg-Ala-Ser(P)-Leu-Gly, corresponding to the local phosphorylation-site sequence in liver pyruvate kinase was synthesized and tested for competitive inhibition of PH7 binding (Table 2 ). The pyruvate kinase phosphopeptide, a substrate for cyclic AMP-dependent protein kinase, did not give significant competition with monoclonal antibody PH7. At 50% inhibition the phosphopeptide concentration was 10 times greater than that for the phosphopeptide corresponding to the phenylalanine hydroxylase phosphopeptide.
When human liver extract (500 ,ug) was separated by SDS/polyacrylamide-gel electrophoresis and tested by immunoblotting with PH7, only the band corresponding to the phosphorylated human liver phenylalanine hydroxylase was detected (Fig. 6, lane 1) . Monoclonal antibody PH9 demonstrated equivalent cross-reactivity with both forms of phenylalanine hydroxylase (Fig. 6,  lane 2) . Moreover, the same result was obtained when the human liver extract was acid-precipitated immediately after homogenization (results not shown). 
DISCUSSION
The epitope of antibody PH7 has been localized to the phosphodecapeptide Gly-Leu-Gly-Arg-Lys-Leu-Ser(P)-Asp-Phe-Gly and some binding has been observed with the phosphopentapeptide Leu-Ser(P)-Asp-Phe-Gly. binds to the phosphodecapeptide at concentrations 103-fold higher than does the parent protein. The difference in binding may suggest other structural features are important. Phosphoserine is not able to displace the phosphorylated enzyme from PH7. This is supported by the observation that the antibody reacts only weakly with the phosphoproteins casein and phosvitin. The phosphodecapeptide Gly-Leu-Gly-ArgLys-Leu-Ser(P)-Asp-Phe-Gly and the phosphopeptide Leu-Arg-Arg-Ala-Ser-Leu-Gly, corresponding to the local phosphorylation site of liver pyruvate kinase, are both phosphorylated by cyclic AMP-dependent protein kinase. However, the pyruvate kinase phosphopeptide reacts weakly with PH7, suggesting a specific PH7-binding epitope on human liver phenylalanine hydroxylase. When fresh and trichloroacetic acidprecipitated human liver extracts were probed with PH7, the monoclonal antibody did not react with human liver extract phosphoproteins other than phosphorylated phenylalanine hydroxylase, even after trichloroacetic acid precipitation of the liver extract to prevent phosphatase action (Fig. 6 ).
The amino acid composition of the 41-residue peptide (Table 1) appears to differ slightly from that indicated by the sequence data (Kwok et al., 1985) . The reason for the inconsistent amino acid data is not clear. One possible explanation is that there may be some error in the nucleotide sequence data. However, the fact that this peptide is blocked at the N-terminus is consistent with it being the N-terminal peptide.
Previous workers have made polyclonal antisera which distinguish phosphorylated and dephosphorylated forms of proteins (Nairn et al., 1982) . A monoclonal antibody reactive with acetylcholine receptor is thought to include phosphate in its epitope because of its reactivity with the phosphoprotein phosvitin (Pizzighella et al., 1983) . A similar requirement for a phosphorylated serine in the epitope appears to exist with monoclonal antibody PH7. A monoclonal antibody to phosphotyrosine has been used to study proteins phosphorylated on the tyrosine residue (Frackelton et al., 1984) .
The present results suggest that it may be possible to construct monoclonal antibodies specific for hypothetical phosphoproteins not purified but for which there is only DNA-sequence-derived information. 
